Moderna and Merck said on Aug. 19 that the Phase 3 INTerpath-001 trial delivered a positive topline readout in resected Stage IIB-IV melanoma, with Intismeran plus Keytruda showing statistically significant and clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival versus Keytruda alone. The study enrolled 1,137 patients, but Moderna has not yet released the hazard ratios, absolute recurrence-rate differences, or overall survival data, so the only firm conclusion for now is that the Phase 3 study met its interim bar. The trial will continue rather than stop early. The report argues that the bigger story is operational. Intismeran is not a one-formula product for every patient. The therapy is built from each patient’s tumor and blood genetic information, with up to 34 neoantigens selected before a personalized mRNA treatment is produced. Moderna’s Maestro digital system coordinates clinical operations, manufacturing, quality control, and logistics across separate production batches. The article also points to upstream data work by Personalis, whose tumor analysis platform has been used by Moderna and Merck since the early V940/mRNA-4157 program, and notes Tempus AI’s planned acquisition of Personalis at about $1.5 billion enterprise value. It pairs that development with Anthropic’s recent protein-design experiment to show a broader shift: AI is moving out of stand-alone software and into real-world research, lab, production, and clinical processes.

Crypto exchanges are pushing deeper into equities, turning stocks into one of the clearest product expansion paths in this market cycle. CoinGecko data cited in the report shows monthly stock perpetual volume across the top 13 crypto trading platforms climbed from about $831 million in July 2025 to roughly $34 billion in May 2026, a jump of nearly 40 times in less than a year. TradFi and RWA perpetuals spanning stocks, commodities and indexes reached $347.17 billion in May 2026 alone, with year-to-date volume above $1.32 trillion. The landscape is no longer limited to synthetic price exposure. Binance, Kraken, OKX, Bitget, Gate, Coinbase and Backpack are each combining different layers of product infrastructure, including direct access to real U.S. stocks and ETFs, tokenized stocks backed 1:1 by underlying securities, onchain-transferable equity tokens, stock perpetuals, CFDs and pre-IPO contracts. Their structures differ in important ways, especially around custody, investor rights, redemption and whether users actually own shares or only gain economic exposure. The report argues that crypto stocks remain early relative to traditional equity markets, with CoinGecko data indicating activity in crypto stock derivatives is still less than 1% of traditional stock market volume. Even so, the segment is moving from a niche RWA experiment toward a core competitive arena for centralized exchanges that want to extend from crypto into broader financial trading.

Crypto stock products are turning into one of the clearest expansion paths for centralized exchanges as they push beyond digital assets and into traditional finance. The competitive set is no longer limited to synthetic price exposure. By 2026, major platforms had rolled out a mix of real stock brokerage, tokenized equities, stock perpetuals, CFDs and pre-IPO products, often inside a single account system. According to CoinGecko figures cited in the source article, monthly trading volume for stock perpetuals across the top 13 crypto trading platforms climbed from about $831 million in July 2025 to roughly $34 billion in May 2026, an increase of nearly 40 times in less than a year. The article also notes that cumulative stock-perpetual volume in the first five months of 2026 had already surpassed the whole of 2025. On the tokenized spot side, xStocks had logged more than $35 billion in cumulative trading volume by July 2026 and nearly 200,000 holders globally, while expanding beyond U.S. stocks and ETFs into Hong Kong, the U.K., Europe and South Korea. The report reviews how Binance, OKX, Bitget, Gate, Kraken, Coinbase and Backpack approach the market through different legal and product structures. It argues that the category now spans four distinct models: traditional brokerage access to real shares, tokenized securities backed by underlying stocks, total-return or synthetic equity tokens, and stock perpetuals or CFDs that do not require 1:1 share backing. The result is a market that is still early by global equity standards, yet increasingly central to how exchanges compete for the next phase of user growth.

Moderna and Merck said an interim Phase 3 analysis of their personalized mRNA cancer therapy, intismeran autogene, used with Keytruda in melanoma patients, met both its primary and key secondary endpoints. The update sent Moderna shares up 176.97% on Aug. 19 to $174.38, lifting the company’s market value from about $25 billion to roughly $69 billion in a single session, while Merck rose more than 9% intraday. The regimen is designed as adjuvant therapy after surgery for resected stage IIB to IV cutaneous melanoma, aiming to reduce recurrence and distant metastasis rather than treat widely metastatic end-stage disease. The trial, INTerpath-001, enrolled 1,137 patients in a 2:1 randomized, double-blind design. Still, the companies have not yet released hazard ratios, confidence intervals, p-values, event counts, absolute recurrence rates, or Kaplan-Meier survival curves from the Phase 3 readout. Earlier Phase 2 data from KEYNOTE-942 showed a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk, but overall survival was not statistically significant. Questions around durability, manufacturing scale, pricing, reimbursement, expansion into other tumor types, and long-term safety remain unresolved.

U.S. equities finished Wednesday modestly higher, according to market data from BIT (Bit.com), with the Dow Jones Industrial Average up 0.22%, the S&P 500 gaining 0.21%, and the Nasdaq rising 0.16%. The standout move came from Moderna, which jumped 176.9%, while Merck added 12.6% after the two companies said their jointly developed personalized mRNA cancer vaccine, intismeran autogene, formerly known as mRNA-4157/V940, combined with Merck’s immunotherapy drug Keytruda, met the primary endpoint and key secondary endpoint in the Phase III INTerpath-001 trial for patients with high-risk melanoma. Semiconductor-related names showed mixed trading, with Marvell Technology up more than 9.8%, SK Hynix up 0.35%, Sandisk down 3.5%, and Micron Technology off 0.39%. Crypto-related stocks also posted strong gains. Strategy rose 11.95% to $103.58 after climbing more than 13% intraday. Coinbase gained 9.05% to $159.47, stablecoin issuer Circle advanced 9.44% to $78.50, and Ethereum treasury company BitMine rose 9.68% to $20.05.

Moderna shares surged about 131% on Wednesday after the company and Merck said their Phase 3 INTerpath-001 trial met key goals in patients with surgically removed stage IIB-IV melanoma. The study tested intismeran autogene, also known as V940 or mRNA-4157, in combination with Keytruda. According to the companies, the regimen met recurrence-free survival and distant-metastasis-free survival endpoints, marking the first positive Phase 3 result for a personalized neoantigen therapy and the first for an mRNA-based cancer treatment. Moderna stock nearly reached $148 after hitting an intraday high of $163, setting a record one-day jump, while Merck shares also rose. The report said the therapy works by sequencing a patient’s tumor, identifying unique mutations, and using mRNA to help the body generate neoantigens that train the immune system to attack cancer. ORTEX co-founder Peter Hillerberg said losses of nearly $100 per shorted share could create the kind of pressure that triggers a squeeze. The trial will continue to track overall survival and other secondary endpoints that have not yet been reported.

The Philadelphia Semiconductor Index extended its decline to 5%, according to data from MSX.COM, as semiconductor stocks broadly moved lower. Among the names cited, Marvell Technology fell more than 7%, while Arm and Intel were each down nearly 7%. Micron Technology lost 5.7%, and Nvidia fell more than 2%. The move reflected broad weakness across the chip sector during the session, with multiple major semiconductor names posting sizable losses at the same time. The figures cited were attributed to MSX.COM data in an Odaily newsflash.

Tiger Global Management made broad portfolio changes in the second quarter, according to a BlockBeats brief published on Aug. 15. On the selling side, the fund cut its holdings in Broadcom by 51.1% to 1.8 million shares, Alphabet Class A by 45.4% to 5.8 million shares, and Taiwan Semiconductor Manufacturing by 12.3% to 4.9 million ADS. It also reduced Microsoft to 2.3 million shares, Meta Platforms Class A to 2.8 million shares, Nvidia to 11.2 million shares, and JD.com to 201,500 ADS. On the buy side, Tiger Global raised its Intel position to 4.3 million shares and opened new stakes in AMD and SpaceX. The new positions were 674,000 shares of AMD and 375,000 shares of SpaceX. The fund also fully exited Netflix during the quarter.